Frontage Laboratories | Top CRO 2022
Pharma Tech Outlook

Pharma Tech Outlook

Frontage Laboratories
One-Stop-Shop for Top-Notch Drug Development Services

Frontage Laboratories: One-Stop-Shop for Top-Notch Drug Development Services

Dr. Song Li, Founder and CEO, Frontage LaboratoriesDr. Song Li, Founder and CEO
Drug development is an extremely time and cost-intensive process. Pharmaceutical, biotechnological, and life sciences companies require avenues to fund their drug development, build robust research teams, and set up well-equipped laboratories. This especially proves to be daunting for life sciences startups and smaller companies with limited resources and research expertise. All this results in severe delays, taking years before the drug even sees the light of the day.

Offering round-the-clock support to fast-track and fulfill the drug development goals of pharma, biotech, and life sciences companies is Frontage Laboratories. “We provide integrated pharmaceutical product development services that clients need at each stage of the drug discovery and development process,” says Dr. Song Li, founder and CEO of Frontage Laboratories. The clinical research organization (CRO) offers a host of comprehensive, cost-effective clinical services that include drug metabolism and pharmacokinetics, bioanalysis, analytical testing, formulation creation, preclinical and clinical trial material manufacturing, preclinical safety and toxicology evaluation, and early phase clinical investigation.

Frontage assists various biotech and pharma companies across the globe in accelerating their compounds through the development process and achieving regulatory approval for their drugs. The company’s qualified team of pharmaceutical industry experts addresses the myriad drug development challenges of life sciences startups as well as that of big pharma. For small pharma companies and startups struggling with a lack of industry expertise, Frontage provides consultations and recommendations on the best course to follow during the development stages. In addition to regular clinical services, Frontage also arranges the necessary funds required by these companies from investors. For big pharma companies, the company engages with external industry experts to expedite their drug development projects.

Frontage’s approach to streamlining drug development projects for clients involves setting up efficient testing methodology associated with preclinical services.

Also, Frontage provides recommendations on the directory requirements and study protocols to clients based on a thorough evaluation of their project. This results in immense time and cost savings for the companies as they get access to the optimal path to conduct their drug discovery and development. Furthermore, the company manufactures tablets, capsules, injectables, and topical products to ease drug administration during clinical trials for clients.

The key differentiators enabling Frontage to deliver unmatched pharmaceutical product development services are its three core strengths— an illustrious scientific team, advanced laboratories, and stringent quality control measures. The company’s highly accomplished scientific team comprising a significant percentage of Masters and Ph.D. degree holders enables Frontage to solve some of the more complex issues surrounding drug development compared to other industry players. In terms of laboratory facilities, the company possesses advanced clinical centers and impressive lab spaces in the US and China furnished with state-of-the-art testing equipment. Moreover, Frontage’s strict quality testing methods are aligned to GCP, GMP, and GRP standards and adhere to FDA regulations, ensuring the best outcomes for clients in their drug development journey.

  • We provide integrated pharmaceutical product development services that clients need at each stage of the drug discovery and development process,” says Dr. Song Li, founder and CEO of Frontage Laboratories


Frontage’s expertise in facilitating and streamlining drug discovery and development has enabled it to serve some of the biggest names in the pharma segment. In the early days of the company, Frontage developed an effective preclinical drug validation method for a leading Philadelphia-based pharma company’s drug testing project, and they continue to be devoted clients. Similarly, for another renowned Boston-based biotech company, Frontage designed a formulation method for testing their nanotechnology-based injectable drug during the preclinical stage. The FDA lauded the method’s efficacy, which served as a decisive factor in the drug getting FDAapproved. With a long streak of success that continues to grow with each passing day, Frontage envisions surging ahead in the world of pharmaceuticals and standing a class apart in the CRO space.

Frontage Laboratories News

Frontage Receives Multiple 2023 CRO Leadership Awards

EXTON - Frontage Laboratories, Inc., a wholly-owned subsidiary of Frontage Holdings Corporation (HK.1521), is proud to once again be named as a CRO Leadership Awards recipient by the Clinical Leader and Life Science Leader magazine. The publication assesses CROs on 20+ performance metrics in ISR's annual CRO Quality Benchmarking survey. Frontage received five awards across all categories including Capabilities, Compatibility, Expertise, Quality, and Reliability across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). In the Compatibility category, Frontage was recognized as a CRO Leadership Award Champion for scoring one standard deviation or more above the weighted average of other CROs. Frontage is honored to have consistently received CRO Leadership awards since 2014.

"CRO selection is one of the most important and strategic decisions for study sponsors in their clinical research programs. We're proud to be recognized by the CRO Leadership Awards across all five categories evaluated – Capabilities, Compatibility, Expertise, Quality, and Reliability. We wish a heartfelt congratulations to all the winners for their outstanding performance and vital contribution to the clinical research industry," said Amit Dua, Vice President, Market Development, Clinical Leader.

Dr. John Lin, President of Frontage, commented, "Frontage is proud to be a recipient of the 2023 CRO Leadership Award. We consistently strive to provide the highest quality services in collaboration with our pharma sponsors in the U.S. and China over many years. We look forward to continuing the expansion of our services globally while maintaining our esteemed industry reputation."

Dr. Abdul Mutlib, CEO of Frontage, said, "Frontage is honored to be recognized as an industry leader year after year by various publications. This is a recognition of our commitment to serving our client's needs throughout their drug discovery and development phases. I sincerely appreciate the hard work, dedication, and collaboration by Frontage's employees enabling us to achieve these awards."

Top 10 CROs - 2022

Company
Frontage Laboratories

Management
Dr. Song Li, Founder and CEO

Description
Frontage Laboratories offers integrated product development services throughout the drug discovery and development stages to pharma, biotech, and life sciences companies. The CRO brings a host of comprehensive clinical services that include drug metabolism and pharmacokinetics, bioanalysis, analytical testing, formulation creation, preclinical and clinical trial material manufacturing, preclinical safety and toxicology evaluation, and early phase clinical investigation. With an illustrious scientific team, advanced laboratories, and stringent quality control measures, Frontage Laboratories expedites the drug development process of clients and plays an instrumental role in achieving regulatory approval for their drugs.